Back to mobile site

Vaxcyte (PCVX) Reiterated at Overweight by Cantor Fitzgerald Afters OPUS-1 Top Line

October 19, 2026 7:29 AM EDT Send to a Friend
Cantor Fitzgerald analyst Carter Gould reiterated an Overweight rating and $120.00 price target on Vaxcyte (NASDAQ: PCVX).The analyst commented, "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login